Foster City, California – The Gilead Sciences, Inc. submits to Japan’s Pharmaceutical and Medical Devices Agency a new drug application. The application is still for approval of sofosbuvir which is a nucleotide polymerase inhibitor used in treating the chronic hepatitis C viral infection.
Gilead Sciences, Inc. has opened trading at $82.18, while its current estimate stands at 126.36 billion dollars. It has outperformed its other Biotechnology peers based on quarterly revenue growth. Its annual growth stands at 0.98 compared to 0.09 as the industry average. Its earnings currently stands at 2.70 per share, compared to the -0.24 sector average. Sales growth of 98.80% is expected along with revenue valuation of $5.30 billion.
Gilead Sciences Inc., is a biopharmaceutical industry. It is geared towards the discovery, development, and commercialization of medicines in treating life-threatening illnesses in North and South Americas, Europe, and Asia-Pacific. The industry has a wide array of products, specifically in treating the macular degeneration, human immunodeficiency virus, Influenza A and B, invasive fungal infections, pulmonary arterial hypertension, respiratory, cardiovascular, and liver diseases. Gilead Sciences Inc. collaborates with Janssen, BMS, and Japan Tobacco in developing and commercializing different products. Its new drug application to Japan is geared mainly in developing treatment for hepatitis C viral infection.